

Resource Summary Report

Generated by [dkNET](#) on Aug 7, 2026

GSVA

RRID:SCR_021058

Type: Tool

Proper Citation

GSVA (RRID:SCR_021058)

Resource Information

URL: <https://www.bioconductor.org/packages/release/bioc/html/GSVA.html>

Proper Citation: GSVA (RRID:SCR_021058)

Description: Open source software R package for assaying variation of gene set enrichment over sample population. Used for microarray and RNA-seq data analysis. Gene set enrichment method that estimates variation of pathway activity over sample population in unsupervised manner.

Abbreviations: GSVA

Synonyms: Gene Set Variation Analysis

Resource Type: software resource, data analysis software, software toolkit, data processing software, software application

Defining Citation: [PMID:23323831](#)

Keywords: Gene set enrichment, variation estimation, pathway activity, sample population, microarray, RNA-seq, data analysis

Funding: ISCIII COMBIOMED ;
Spanish MINECO ;
NCI U54 CA149237

Availability: Free, Available for download, Freely available

Resource Name: GSVA

Resource ID: SCR_021058

License: GPL

Record Creation Time: 20220129T080353+0000

Ratings and Alerts

No rating or validation information has been found for GSVA.

No alerts have been found for GSVA.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 333 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Chen D, et al. (2026) Spatially Resolved Multiomics Reveals Metabolic Remodeling and Autophagy Activation in Adamantinomatous Craniopharyngiomas. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e16965.

Li S, et al. (2026) Spatial transcriptomics uncovers lipid metabolic dysregulation driving immune-stroma crosstalk in Sjögren's Disease. EBioMedicine, 123, 106074.

Zhao C, et al. (2026) Progranulin promotes glioma progression via interaction with cathepsin D and serves as a diagnostic and prognostic biomarker. Discover oncology, 17(1), 336.

Wang Q, et al. (2026) Iron diminishes immunosuppressive macrophages and enhances anti-PD-1 immunotherapy in breast cancer models. Journal of experimental & clinical cancer research : CR, 45(1).

Yang J, et al. (2026) A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(12), 2479.

Kelley RK, et al. (2026) T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(4), 694.

Lee JB, et al. (2026) Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer. ESMO open, 11(2), 106057.

Wang XX, et al. (2026) Modulating the tumor immune phenotypes by radiotherapy: formulating and validating the combination therapy of radiation, PD-L1, and TIM-3 blockade in colorectal cancer. Journal for immunotherapy of cancer, 14(2).

Xu S, et al. (2026) Advantages of magnetic compression in rat colonic anastomosis: a comparative study with a transcriptomic perspective. *Scientific reports*, 16(1).

Moreira Gabriel E, et al. (2026) Pharmacological and genetic modulation of IL-32 expression in intestinal epithelial cells does not impact HIV-1 outgrowth in co-cultured CD4+ T-cells. *Frontiers in immunology*, 17, 1769388.

Dziagwa C, et al. (2026) Disruption of tRNA threonylation triggers RIG-I mediated anti-tumour immune response. *Nature communications*, 17(1).

Xia Z, et al. (2026) PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer. *Cancer research*, 86(12), 3040.

Xia P, et al. (2026) CD27 expression is a clinically accessible biomarker for predicting immunotherapy response in melanoma. *NPJ precision oncology*, 10(1).

Liu B, et al. (2026) Shared molecular features and candidate pathways underlying gastric cancer-depression comorbidity: a systems biology analysis. *Frontiers in bioinformatics*, 6, 1836419.

Peabody I, et al. (2026) An NT5E loss-of-function variant permits tissue inflammation and hypertension in systemic lupus erythematosus. *iScience*, 29(6), 116017.

Maraszek KE, et al. (2026) A targetable opioid/cancer associated fibroblast axis drives extracellular matrix remodeling and tumor aggressiveness in pancreatic cancer. *bioRxiv* : the preprint server for biology.

Zhou Z, et al. (2026) The lipid-metabolic enzyme HSD17B12 drives lysosomal degradation of PD-L1 potentiating anti-tumor immunity in a mouse model. *PLoS biology*, 24(1), e3003603.

Hu YM, et al. (2026) Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types. *Cancer research communications*, 6(1), 17.

Tao Y, et al. (2026) TENT5A Maintains MYC mRNA Stability to Enhance Osteosarcoma Stemness. *Cancer research*, 86(9), 2161.

Ni Z, et al. (2026) Integrated and clinical validation of helicase-like transcription factor as a biomarker for hepatocellular carcinoma. *BMC cancer*, 26(1).